1. Introduction {#sec1-ijerph-15-01284}
===============

The reliance of public health and animal health on antimicrobials since the last century is well known and undisputable \[[@B1-ijerph-15-01284]\]. Paradoxically, this reliance (sometimes, over-reliance) and its attendant successes have evolved to become a threat to global animal and human health through the phenomenon of antimicrobial resistance (AMR) \[[@B2-ijerph-15-01284]\]. Following the development and use of an antimicrobial, various pathogens, in their attempt to survive or evade current and new antimicrobials, undergo evolutionary processes, which results in a short to long term resistance \[[@B3-ijerph-15-01284]\]. AMR is the ability of a microorganism (bacteria, viruses, and certain parasites) to prevent an antimicrobial (antibiotics, antivirals, and antimalarials) from working against it \[[@B4-ijerph-15-01284]\]. This may lead to resultant ineffectiveness of standard treatments and the infections may persist, with a higher likelihood of spread \[[@B5-ijerph-15-01284]\]. The World Health Organization (WHO) presented the level of exposure of the challenges of AMR through the report of the general worldwide situation analysis \[[@B4-ijerph-15-01284]\]. This magnitude of threat associated with AMR then received the highest level of political commitment from world leaders and was discussed at the United Nations General Assembly in 2016, where a political declaration on AMR was issued \[[@B6-ijerph-15-01284]\]. Hitherto, WHO and the Food and Agriculture Organization of the United Nations (FAO) produced some fundamental documents toward curbing the threat of AMR. These include the WHO Global action plan on antimicrobial resistance and the FAO action plan on antimicrobial resistance 2016--2020, respectively \[[@B7-ijerph-15-01284],[@B8-ijerph-15-01284]\]. The report from the monitoring of the global action plan by FAO has suggested and recommended the need for situation analysis and production of action plans for individual countries \[[@B9-ijerph-15-01284]\].

Food producing animals are linked to humans via the food chain and shared environment \[[@B10-ijerph-15-01284]\]. Thus, a One Health approach is necessary to study and understand how to control burdens of AMR, including those presented through foodborne transmission routes \[[@B11-ijerph-15-01284],[@B12-ijerph-15-01284]\], as well as create a sound and broad-based antimicrobial stewardship program worldwide \[[@B12-ijerph-15-01284]\].

Nigeria is also confronted with the burdens of AMR. The Nigerian Centre for Disease Control (NCDC), in collaboration with other institutions, has made efforts to develop an approach to combat AMR using an evidence-based method. Meanwhile, NCDC (2017) reported that Nigeria has experienced huge resistance to antimicrobials in humans, especially in sepsis, respiratory, and diarrheal infections. These include childhood-related life-threatening diseases and are supported by empirical evidence, which are replete and scattered in peer-reviewed and grey literature, as well as commissioned reports \[[@B13-ijerph-15-01284]\]. In addition, the situation analysis and recommendations on AMR and drug use in Nigeria has recently been documented \[[@B13-ijerph-15-01284]\]. This document still requires detailed information about several sources of AMR, creating a gap in the trend, status, and situation of AMR arising from food animals and the environment. This study fills that gap through a systematic review of published studies and available reports. Specifically, the study collates, curates, and analyzes data on AMR in Nigeria related to food producing animals and the environment, and the immediate human link as contributors to the burdens of AMR in Nigeria. This study is required as a reference source towards the development of a good antimicrobial stewardship program by stakeholders through the "One Health Platform" for Nigeria.

2. Materials and Methods {#sec2-ijerph-15-01284}
========================

2.1. Research Question(s) {#sec2dot1-ijerph-15-01284}
-------------------------

We developed some research questions that were used as guides during the study to pursue the attainment of our objectives towards establishing the situation analysis of AMR in the Nigerian environment from food animals. What was the status of antimicrobial resistance in the food producing animals and the environment in Nigeria in the previous studies? What was the pattern of resistance among the classes of antimicrobials tested? What was the status of resistance among the common Nigerian antiseptics and disinfectants that sought to control pathogens at the environmental interface? What were the common organisms and their AMR resistance patterns studied in Nigeria to date?

2.2. Search Design {#sec2dot2-ijerph-15-01284}
------------------

We searched specific databases (Pub Med-NCBI, Google Scholar, Cabdirect, Medline, Embase, Cochrane, and African Journals Online) and various institutional repository of Nigeria using broad terms, "antimicrobial, resistance, and Nigeria". Where necessary, search terms were stated as strings: Antimicrobial resistance OR Antibiotic resistance OR Antibiotic residue OR Antimicrobial susceptibility OR Antibiotic abuse OR Antibiotic misuse AND Nigeria AND animals; "animals" was substituted with environment and different animal names (poultry, goat, sheep, cattle, camel, pig, etc.). References in the identified materials were also searched and contacted. This effort yielded a broad list of 2393 studies from all sources by the contributors. After removing duplicates, we obtained 435 studies, which were screened to 235 studies by excluding studies conducted prior to the year, 2000, and those with Nigerian authors or affiliations, but focused on samples from outside Nigeria. Upon assessment, we obtained 139 publications and a further 80 were excluded to give 59 publications included in the review and analysis. Each publication was treated as a study, which contains single or multiple reports. The 80 studies excluded did not directly relate to the objectives or yielded information that could be subjected to organized peer review and data analysis. The 59 included studies were sorted into three categories of 42 antimicrobial resistance studies \[[@B14-ijerph-15-01284],[@B15-ijerph-15-01284],[@B16-ijerph-15-01284],[@B17-ijerph-15-01284],[@B18-ijerph-15-01284],[@B19-ijerph-15-01284],[@B20-ijerph-15-01284],[@B21-ijerph-15-01284],[@B22-ijerph-15-01284],[@B23-ijerph-15-01284],[@B24-ijerph-15-01284],[@B25-ijerph-15-01284],[@B26-ijerph-15-01284],[@B27-ijerph-15-01284],[@B28-ijerph-15-01284],[@B29-ijerph-15-01284],[@B30-ijerph-15-01284],[@B31-ijerph-15-01284],[@B32-ijerph-15-01284],[@B33-ijerph-15-01284],[@B34-ijerph-15-01284],[@B35-ijerph-15-01284],[@B36-ijerph-15-01284],[@B37-ijerph-15-01284],[@B38-ijerph-15-01284],[@B39-ijerph-15-01284],[@B40-ijerph-15-01284],[@B41-ijerph-15-01284],[@B42-ijerph-15-01284],[@B43-ijerph-15-01284],[@B44-ijerph-15-01284],[@B45-ijerph-15-01284],[@B46-ijerph-15-01284],[@B47-ijerph-15-01284],[@B48-ijerph-15-01284],[@B49-ijerph-15-01284],[@B50-ijerph-15-01284],[@B51-ijerph-15-01284],[@B52-ijerph-15-01284],[@B53-ijerph-15-01284],[@B54-ijerph-15-01284],[@B55-ijerph-15-01284]\], 16 antimicrobial residue studies \[[@B56-ijerph-15-01284],[@B57-ijerph-15-01284],[@B58-ijerph-15-01284],[@B59-ijerph-15-01284],[@B60-ijerph-15-01284],[@B61-ijerph-15-01284],[@B62-ijerph-15-01284],[@B63-ijerph-15-01284],[@B64-ijerph-15-01284],[@B65-ijerph-15-01284],[@B66-ijerph-15-01284],[@B67-ijerph-15-01284],[@B68-ijerph-15-01284],[@B69-ijerph-15-01284],[@B70-ijerph-15-01284],[@B71-ijerph-15-01284]\], and 1 antiseptic or disinfectants study \[[@B72-ijerph-15-01284]\]. The PRISMA-style flowchart was modified and used for this analytical review ([Figure S1](#app1-ijerph-15-01284){ref-type="app"}) \[[@B73-ijerph-15-01284]\].

2.3. Analysis {#sec2dot3-ijerph-15-01284}
-------------

The number of publications ([Table 1](#ijerph-15-01284-t001){ref-type="table"}a), diversity of methods of data reporting, multiple appearances of study populations reported ([Table 1](#ijerph-15-01284-t001){ref-type="table"}b) in each study, and the objectives of the various studies of the 59 publications we reviewed made it expedient to find a system of accommodating the information through a uniform standard for data harmonization and interpretation in line with the objectives of this study. The various methods of data analysis in all the studies were reviewed to form a unified scale as presented in [Table 2](#ijerph-15-01284-t002){ref-type="table"}. This scale was developed to harmonize the diverse data for analyzing the situation of AMR in Nigeria within the 42 antimicrobial resistance studies (AMRS) and 16 antimicrobial residue studies (ARS). Therefore, the data of reported resistance and residue in the studies were categorized and interpreted according to the standard developed ([Table 2](#ijerph-15-01284-t002){ref-type="table"}). Percentage in [Table 2](#ijerph-15-01284-t002){ref-type="table"} referred to the percentage (portion) of resistant microbe populations (species) per study. The methods used in most studies were descriptive statistics simple percentages. Some ARS reports were presented in relation to the FAO or WHO standard of maximum residue limit (MRL) at the time of publication. In such studies, the report where no residue was found is categorized as "No residue", the report where there was residue below standards is categorized as "Low residue", and the report where the mean residue level was above the MRL is categorized as "Very high residue". Analysis of the data was then done with MS Excel using simple descriptive statistical analysis, pivot tables, and charts.

3. Results {#sec3-ijerph-15-01284}
==========

We observed that few studies were undertaken before 2009, with no AMRS, but only four ARS, after which there was an increase in AMRS research from 2009 until recently ([Table 1](#ijerph-15-01284-t001){ref-type="table"}a). The study population involved were environment, cattle, poultry, pig, goat, vegetables, human, bats, camel, sheep, and fish listed in descending order of the number of reports and the type of resistance reported ([Table 1](#ijerph-15-01284-t001){ref-type="table"}b). The study populations appeared singly or in multiple in a study ([Table 1](#ijerph-15-01284-t001){ref-type="table"}b). Also, each study reported from one zone or several geopolitical zones of Nigeria ([Figures S2 and S3](#app1-ijerph-15-01284){ref-type="app"}). Our review revealed that these studies on samples from animals and the environment carried out between 2000 and 2016 fell into three categories ([Table 1](#ijerph-15-01284-t001){ref-type="table"}b).

3.1. Antimicrobial Resistance Studies (AMRS) {#sec3dot1-ijerph-15-01284}
--------------------------------------------

This category included 42 studies, with the inclusive eligibility criteria in which diverse phenotypic or genotypic methods were utilized (\[[@B14-ijerph-15-01284],[@B15-ijerph-15-01284],[@B16-ijerph-15-01284],[@B17-ijerph-15-01284],[@B18-ijerph-15-01284],[@B19-ijerph-15-01284],[@B20-ijerph-15-01284],[@B21-ijerph-15-01284],[@B22-ijerph-15-01284],[@B23-ijerph-15-01284],[@B24-ijerph-15-01284],[@B25-ijerph-15-01284],[@B26-ijerph-15-01284],[@B27-ijerph-15-01284],[@B28-ijerph-15-01284],[@B29-ijerph-15-01284],[@B30-ijerph-15-01284],[@B31-ijerph-15-01284],[@B32-ijerph-15-01284],[@B33-ijerph-15-01284],[@B34-ijerph-15-01284],[@B35-ijerph-15-01284],[@B36-ijerph-15-01284],[@B37-ijerph-15-01284],[@B38-ijerph-15-01284],[@B39-ijerph-15-01284],[@B40-ijerph-15-01284],[@B41-ijerph-15-01284],[@B42-ijerph-15-01284],[@B43-ijerph-15-01284],[@B44-ijerph-15-01284],[@B45-ijerph-15-01284],[@B46-ijerph-15-01284],[@B47-ijerph-15-01284],[@B48-ijerph-15-01284],[@B49-ijerph-15-01284],[@B50-ijerph-15-01284],[@B51-ijerph-15-01284],[@B52-ijerph-15-01284],[@B53-ijerph-15-01284],[@B54-ijerph-15-01284],[@B55-ijerph-15-01284]\], [Tables S1--S3](#app1-ijerph-15-01284){ref-type="app"}). These studies sought to detect the presence and extent of AMR in collected samples with a selected panel of antibiotics. Cumulatively, these 42 studies tested 68 antimicrobials ([Table 3](#ijerph-15-01284-t003){ref-type="table"}) belonging to different classes and generations of antibiotics from the first to fourth generation of antibiotics, including others that cannot be classified based on generations that were placed on "no generational classification" (NGC) in the course of the analysis ([Table 3](#ijerph-15-01284-t003){ref-type="table"}, [Figure S4](#app1-ijerph-15-01284){ref-type="app"}a,b, and [Figure S5](#app1-ijerph-15-01284){ref-type="app"}a). These resulted in the report of 1139 antimicrobial resistance findings. Out of the 42 studies, only one study on camel samples \[[@B45-ijerph-15-01284]\] did not report multidrug resistance (MDR). Two studies \[[@B30-ijerph-15-01284],[@B38-ijerph-15-01284]\] reported low MDR in cattle and camel samples, and the remaining 39 studies confirmed various patterns of MDR. The AMRS were based on 18 organisms (genus) with species or serovars appearing at least once ([Figure 1](#ijerph-15-01284-f001){ref-type="fig"}). The five most important pathogens in which AMR testing was carried out were *E. coli*, *Salmonella* serovars, *Staphylococcus aureus*, *Pseudomonas* spp., and *Klebsiella* spp. *Enterococcus* spp., *Vibrio* spp., *Proteus* spp., and *Listeria* spp. are other microbes used by researchers in AMRS ([Figure 1](#ijerph-15-01284-f001){ref-type="fig"}).The nationwide geographical distribution pattern based on geopolitical zones demonstrated that the highest number of reports were from South West Nigeria (44 studies) and, in descending order, from South South (28), North West (16), North Central (10), North East (4), and the lowest was South East (1), which showed poor distribution of studies at the North East and South East ([Figure 2](#ijerph-15-01284-f002){ref-type="fig"}, [Figure S2](#app1-ijerph-15-01284){ref-type="app"}).

### 3.1.1. Antimicrobial Resistance According to Generation of Antibiotics {#sec3dot1dot1-ijerph-15-01284}

Antimicrobial resistance within the generational classification of antibiotics used in AMRS ([Table 3](#ijerph-15-01284-t003){ref-type="table"}) revealed that the 68 antibiotics used in all 42 studies involved first, second, third, and fourth generations, and NGC. The generational classification ([Table 3](#ijerph-15-01284-t003){ref-type="table"}) was done using the WHO and the World Organization for Animal Health (OIE) lists of critically important antimicrobial in humans and animals \[[@B74-ijerph-15-01284],[@B75-ijerph-15-01284],[@B76-ijerph-15-01284]\]. This classification is, essentially, based on the spectrum of activity, which increased from first to fourth generation, implying narrow to broad coverage of antibiotics' action \[[@B74-ijerph-15-01284]\]. Cumulatively, of the 1139 antimicrobial report findings, the NGC had the highest number of reports of 537 in the studies of different resistance levels, followed by second and third generation at 210 and 205 reports, respectively; then, fourth generation at 100 and first generation at 86 reports of the resistance findings ([Table 3](#ijerph-15-01284-t003){ref-type="table"}, [Figure S4](#app1-ijerph-15-01284){ref-type="app"}a). The pattern of resistance ([Figure S4](#app1-ijerph-15-01284){ref-type="app"}b) based on proportional percentages of reports showed about 30% of reports on third and fourth generation, and NGC antimicrobials; 20% of first and second generation had very high levels of resistance. It was only 30% of the reports on first, second, and fourth generation, then 20% of third and NGC antimicrobials that had no resistance ([Table 3](#ijerph-15-01284-t003){ref-type="table"}, [Figure S4](#app1-ijerph-15-01284){ref-type="app"}b).

### 3.1.2. Resistance Level within the Classes of Antibiotics {#sec3dot1dot2-ijerph-15-01284}

The 1139 antimicrobial report findings from the 68 antimicrobials included in the panels of all the studies (AMRS) belonged to 19 classes of antibiotics: Aminoglycoside, Ansamycin, Carbolic acid, Diaminopyrimidine inhibitor (DPI), Furan, Glycopeptide, Macrolide, Organophosphate, Oxazolidinone, Phenicol, Polypeptide, Quinolone, Steroid, Streptogramins, Sulfonamides, Sulfonamides + Diaminopyrimidine combinations (SDPI), Tetracycline, β-lactam, and β-lactam + β-lactamase inhibitor combination ([Table 3](#ijerph-15-01284-t003){ref-type="table"} and [Table 4](#ijerph-15-01284-t004){ref-type="table"}). The number of appearances along the resistance level of these classes ([Table 4](#ijerph-15-01284-t004){ref-type="table"}) revealed β-lactam, Quinolone, and Aminoglycoside as the predominant classes studied. The distribution of these classes along the generation showed that β-lactam derivatives, Quinolone, polypeptide, and streptogramins were the antibiotics with generational classification, while others fall in NGC ([Table 3](#ijerph-15-01284-t003){ref-type="table"} and [Table 4](#ijerph-15-01284-t004){ref-type="table"}, [Figure S5](#app1-ijerph-15-01284){ref-type="app"}a,b). Therefore, the distribution of resistance within them have great connected implications in human health as they are mostly used in treating disease conditions in hospitals \[[@B76-ijerph-15-01284]\].

Using the developed standard ([Table 2](#ijerph-15-01284-t002){ref-type="table"}), we observed the distribution pattern of resistance levels within classes ([Table 4](#ijerph-15-01284-t004){ref-type="table"}) demonstrated that polypeptides and carbolic acids were the only classes where organisms studied had all the reports to be the "no resistance" category ([Table 4](#ijerph-15-01284-t004){ref-type="table"}). Oxazolidinone, Ansamycim, streptogramins, and Aminoglycosides antibiotics were, at best, categorized as "very low resistance". Meanwhile, phenicol, β-lactam DPI, SDPI, furan, glycopeptides, macrolides, organophosphate, and tetracycline were, at best, of the "very high resistance" category. The highest level of resistance within the resistance pattern distributions among the antibiotic classes were in steroids and sulfonamides, with 70% of the reports on them having "high resistance" to "very high resistance" ([Table 4](#ijerph-15-01284-t004){ref-type="table"}, [Figure S5](#app1-ijerph-15-01284){ref-type="app"}a,b). Each class had peculiar patterns of resistance among the antibiotics belonging to them, which is important for further exposure of the situation of AMR.

#### β-lactam Derivatives

These were the most tested, constituting 32.4% of all classes of antimicrobials in this study ([Table 4](#ijerph-15-01284-t004){ref-type="table"}). The β-lactam combinations consisted of β-lactam 27% and β-lactam combinations (β-lactam and β-lactamase inhibitors) at 5.4%. The combinations were supposed to improve the sensitivity of the antibiotics against resistant organisms. However, in this study, the organism tested demonstrated higher levels of resistance to β-lactam combinations (19/61) over β-lactam (80/308), which reported very high resistance levels ([Table 4](#ijerph-15-01284-t004){ref-type="table"}, [Figure 3](#ijerph-15-01284-f003){ref-type="fig"}a, [Figure S6](#app1-ijerph-15-01284){ref-type="app"}). We observed Amoxycillin-clavunalic acid as one of the most studied β-lactam derivatives, with organisms showing the highest resistance levels to it among the β-lactam combinations, while Piperacillin-tazobactam was the most sensitive, with a lesser proportion of reports of resistance among β-lactam combinations ([Table 3](#ijerph-15-01284-t003){ref-type="table"} and [Table 4](#ijerph-15-01284-t004){ref-type="table"}, [Figure 3](#ijerph-15-01284-f003){ref-type="fig"}a). Among the β-lactams, the third generation antibiotics were the most researched, with Ampicillin and Amoxycillin highest in study rate and also with the highest number of reported resistance, with above 50% of reports on them having very high resistance ([Figure 3](#ijerph-15-01284-f003){ref-type="fig"}a, [Figure S6](#app1-ijerph-15-01284){ref-type="app"}). Among all β-lactam derivatives, cefalexin in second generation, Ceftioufur in third generation, and ertapenem in NGC were the only antimicrobials that had all reports on them to be "no resistance" ([Figure 3](#ijerph-15-01284-f003){ref-type="fig"}a, [Figure S6](#app1-ijerph-15-01284){ref-type="app"}). All other β-lactams had various patterns of resistance level.

#### Quinolones

This was the second most studied (21.1%) class of antibiotics ([Table 4](#ijerph-15-01284-t004){ref-type="table"}). It comprised nine antimicrobials, with Ciprofloxacin as the most studied. Lomeofloxacin, of the second generation antibiotics, had the highest resistance level, with over 65% of its reports being "high resistance" to "very high resistance" ([Figure 3](#ijerph-15-01284-f003){ref-type="fig"}b, [Figure S7](#app1-ijerph-15-01284){ref-type="app"}). The pattern of resistance had little difference along the generation within this class.

#### Aminoglycosides

These constituted 17.77% of the studied antibiotics ([Table 4](#ijerph-15-01284-t004){ref-type="table"}), with gentamycin and streptomycin dominating the antibiotics researched in this group. Streptomycin had the highest level of resistance from organisms tested, with a proportion of 40% of its report to be "high to very high resistance" ([Figure 3](#ijerph-15-01284-f003){ref-type="fig"}c, [Table 3](#ijerph-15-01284-t003){ref-type="table"} and [Table 4](#ijerph-15-01284-t004){ref-type="table"}, [Figure S8](#app1-ijerph-15-01284){ref-type="app"}). Apramycin was the only antibiotic that was not resisted; all reports on it had "no resistance", while spectinomycin had 80% of its reports with no resistance. The antibiotics in this class demonstrated various patterns of resistance levels ([Figure 3](#ijerph-15-01284-f003){ref-type="fig"}c, [Figure S8](#app1-ijerph-15-01284){ref-type="app"}).

#### Macrolide, Phenicol, and Tetracycline

All these three classes belonged to the NGC. Tetracycline, chloramphenicol, and erythromycin dominated, in descending order, respectively. Tetracycline had the highest level of resistance, with 58% of its report to be "high" to "very high resistance" from the organisms researched. It was followed by erythromycin (50%) and chloramphenicol (40%) had "high" to "very high resistance", then clindamycin, with 60% of reports on it being "high resistance". Tigercycline was the only one that had all the reports on it as "no resistance" and florfenicol, with 65% as no resistance ([Figure 3](#ijerph-15-01284-f003){ref-type="fig"}d, [Figure S9](#app1-ijerph-15-01284){ref-type="app"}).

#### Sulfonamides Derivatives

All the sulfonamides studied belonged to NGC. The three classes and antibiotics studied were Diaminopyrimidine inhibitor (Trimethroprim), Sulfonamides (sulfamethoxazole, sulphadimidine, and triple sulphur), and sulfonamides-diaminopyrimidine inhibitor combination (co-trimoxazole). The reported proportional resistance level in these classes of antibiotics was the most heightened. The combination (co-trimoxazole) was the most studied and 55% of the studies on it reported "high" to "very high resistance level" from organisms studied. The triple sulphur had only one report and the study reported "very high resistance" level to it. Sulphadimidine had eight out of nine reports (90%) to be "very high resistance level", while trimethoprim and sulfamethoxazole both had 55% that reported a "high" to "very high resistance" level ([Figure 3](#ijerph-15-01284-f003){ref-type="fig"}e, [Table 4](#ijerph-15-01284-t004){ref-type="table"}, [Figure S10](#app1-ijerph-15-01284){ref-type="app"}).

#### Other Classes of Antibiotics

The other classes contributed a minute number of report findings, with each class consisting of one antibiotic only; hence, they were pooled together for analysis. Among them, nitrofuran was the most studied and had a high resistance level like vancomycin and fosfomycin, with 50% of the reports having a "high" to "very high resistance" from the organisms studied. In this group, colistin and mupirocin were the most sensitive because they had all reports on them as the "no resistance" level; rifampicin had all its report as "very low resistance", while teicoplan had the highest resistance, with all the reports on it as "very high resistance" from organisms studied. Then fusidic acid responded to the isolates, with about 70% of the reports to be "very high resistance" ([Figures S11 and S12](#app1-ijerph-15-01284){ref-type="app"}).

### 3.1.3. Resistance along the Organisms Studied {#sec3dot1dot3-ijerph-15-01284}

The AMRS were based on 18 organisms (genus), with species or serovars appearing at least once ([Figure 1](#ijerph-15-01284-f001){ref-type="fig"}). The organisms' appearance, in descending order, were: *Escherichia coli*, *Salmonella*, *Staphylococcus*, *Pseudomonas*, *Klebsiella, Bacillus*, *Enterococcus*, *Proteus*, *Vibrio*, *Listeria*, *streptococcus*, *Citrobacter*, *Aerobacter*, *Clostridium*, *Enterobacter*, *Micrococcus*, and *Serratia* ([Figure 1](#ijerph-15-01284-f001){ref-type="fig"}). The distribution of the organisms studied yearly at geopolitical zones demonstrated some organisms were studied more in particular regions or geopolitical zones of Nigeria ([Figure 2](#ijerph-15-01284-f002){ref-type="fig"}).

#### *Escherichia coli* (*E. coli*)

It was the most studied organism (25%) in Nigeria, but had a skewed distribution, with a higher concentration of *E. coli* studies in South West Nigeria and none in the North East and South East ([Figure 2](#ijerph-15-01284-f002){ref-type="fig"}). The distribution of the studies revealed that 57 antibiotics were used to test AMR in *E. coli* isolates, with gentamycin, tetracycline, ciprofloxacin, cotrimoxazole, ampicillin, streptomycin, amoxicillin-clavulanic acid, ofloxacin, ceftriaxone, nitrofuran, perfloxacin, amoxicillin, nalidixic acid, chloramphenicol, cefuroxime, ceftazidime, neomycin, and sparfloxacin being the most prominent in descending order, respectively ([Figure 4](#ijerph-15-01284-f004){ref-type="fig"}a). All the reports on *E. coli* isolates revealed "no resistance" to Apramycin, cefepime, cefoxitin, ceftiofur, colistin, florfenicol, Imipenem, meropenem, vacomycin, cefazoline, ertapenem, and tigecycline in the studies that incorporated into the panel of antimicrobial tested. The *E. coli* isolates researched showed "very-low resistance" to "no-resistance" levels in some antibiotics: Amikacin, aztreonam, norfloxacin, ofloxacin, tobramycin, cefalotin, ticarcillin clavulanate, and cefpodoxime in all reports that used them. However, all reports had a "very high resistance" level to cloxacillin, penicillin, teicoplanin, and sulphadimidine where they were included. We observed other various patterns of resistance levels to the remaining antibiotics studied ([Figure 4](#ijerph-15-01284-f004){ref-type="fig"}a, [Figure S13](#app1-ijerph-15-01284){ref-type="app"}).

#### *Salmonella* 

It was the second most studied organism (14%) in all geopolitical zones, except the South East and South South where there were none ([Figure 1](#ijerph-15-01284-f001){ref-type="fig"} and [Figure 2](#ijerph-15-01284-f002){ref-type="fig"}). The distribution of the studies revealed that 27 antibiotics were used to test for AMR in *Salmonella* isolates, with a close distribution in the number of appearances of individual antibiotics ([Figure 4](#ijerph-15-01284-f004){ref-type="fig"}b). The pattern of resistance reported showed that *Salmonella,* studied in all the reports, had no resistance to apramycin, aztreonam, cefotaxime, ceftiofur, colistin, pefloxacin, and co-trimoxazole. We observed that florfenicol, neomycin, ofloxacin, and spectinomycin, respectively, had 40%, 50%, 50%, and 30% of the report on them to be "very low resistance", but had the remaining 60%, 50%, 50%, and 70% of their reports as the "no resistance" category. Cefalotin and kanamycin had all their reports as the "very low resistance" category. However, all reports on amoxicillin, enrofloxacin, and triple sulphur had "very high resistance". Other various patterns of resistance were observed in the remaining antibiotics studied ([Figure 4](#ijerph-15-01284-f004){ref-type="fig"}b, [Figure S14](#app1-ijerph-15-01284){ref-type="app"}).

#### *Staphylococcus* 

This genus was the third most studied (12%) pathogen for AMR in Nigeria, with the widest spread across all geopolitical zones ([Figure 1](#ijerph-15-01284-f001){ref-type="fig"} and [Figure 2](#ijerph-15-01284-f002){ref-type="fig"}). The distribution of the studies of all antibiotics used revealed that 32 antibiotics were used to test the AMR of *Staphylococcus* isolates ([Figure 4](#ijerph-15-01284-f004){ref-type="fig"}c). The pattern of resistance reported for *Staphylococcus* showed that all studies that tested cefuroxime, nitrofuran, mupirocin, and cefalexin revealed "no resistance". All that tested rifampicin and tombromycin reported "very low resistance". Only two studies reported on linezolid, with one each of "very low resistance" and "no resistance", and the only study that tested trimethoprim on *Staphylococcus* showed "low resistance" ([Figure 4](#ijerph-15-01284-f004){ref-type="fig"}c). However, the two reports on ampicillin had "very high resistance" for *Staphylococcus* isolates. Other patterns (mixed) for the remaining antibiotics tested were observed ([Figure 4](#ijerph-15-01284-f004){ref-type="fig"}c, [Figure S15](#app1-ijerph-15-01284){ref-type="app"}).

#### *Pseudomonas* 

This represents the fourth most studied organism (11%) for AMR in Nigeria and had a spread similar to *E. coli* research ([Figure 1](#ijerph-15-01284-f001){ref-type="fig"} and [Figure 2](#ijerph-15-01284-f002){ref-type="fig"}). The distribution of the studies of all antimicrobials used revealed that 38 antimicrobials were used to test the AMR in *Pseudomonas* isolates ([Figure 4](#ijerph-15-01284-f004){ref-type="fig"}d). Unlike other organisms, there were no antibiotics from the 38 tested with *Pseudomonas* without resistance ([Figure 4](#ijerph-15-01284-f004){ref-type="fig"}d). There was "very high resistance" by all *Pseudomonas* studied to amoxicillin, amoxicillin-clavunanic acid, ampicillin-cloxacillin, cefuroxime, meropenem, mezlocillin, and teicoplanin and "high resistance" to cefotaxime, erythromycin, nitrofuran, piperacillin, tobramycin, ticarcillin clavulanate, cefoperazone, lomeofloxacin, and fosfomycin ([Figure 4](#ijerph-15-01284-f004){ref-type="fig"}d). All reports of studies that tested chloramphenicol with *Pseudomonas* spp. had 75% of them to be "very high resistance" and the remaining 25% of reports were "high resistance". Various resistance patterns were observed in the remaining antibiotics studied ([Figure 4](#ijerph-15-01284-f004){ref-type="fig"}d, [Figure S16](#app1-ijerph-15-01284){ref-type="app"}).

#### *Klebsiella* 

This is the fifth most studied organism and contributed 9% of the overall studies for AMR in Nigeria, with spread across four out of the six geopolitical zones (South West, South South, North West, and North Central) of Nigeria ([Figure 1](#ijerph-15-01284-f001){ref-type="fig"} and [Figure 2](#ijerph-15-01284-f002){ref-type="fig"}). The distribution pattern of the appearance of all antimicrobials used revealed that 33 antimicrobials were used to test the AMR of *Klebsiella* isolates ([Figure 4](#ijerph-15-01284-f004){ref-type="fig"}e). All the *Klebsiella* spp. studied demonstrated "no resistance" to amikacin, aztreonam, cefotaxime, ceftazidime, piperacillin-texobactam, tobramycin, mezlocillin, ticarcillin clavulanate, and cefoperazone and "low resistance" to cefuroxime and levofloxacin; but, "very high resistance" to ampicillin-cloxacillin, nitrofuran, lomeofloxacin, teicoplanin, fosfomycin, and sulphadimidine ([Figure 4](#ijerph-15-01284-f004){ref-type="fig"}a). Meanwhile, it demonstrated a high proportion of "very high resistance" in amoxicillin (60%), amoxicillin-clavunanic acid (75%), ampicillin (75%), chloramphenicol (50%), erythromycin (50%), neomycin (33%), and co-trimoxazole (80%) ([Figure 4](#ijerph-15-01284-f004){ref-type="fig"}e, [Figure S17](#app1-ijerph-15-01284){ref-type="app"}).

#### Other Organisms

All other organisms that made minute contributions were pooled together for analysis. They were spread across the four geopolitical zones of South West, South South, North West, and North Central of Nigeria ([Figure 1](#ijerph-15-01284-f001){ref-type="fig"} and [Figure 2](#ijerph-15-01284-f002){ref-type="fig"}). Analysis revealed 43 antimicrobials were used to test for AMR in these organisms ([Figure 4](#ijerph-15-01284-f004){ref-type="fig"}f). The organisms were *Proteus, Listeria, Enterococcus, Enterobacter, Citrobacter, Aerobacter, Vibrio, Streptococcus, Serratia, Micrococcus, Bacillus,* and *Clostridium* ([Figure 1](#ijerph-15-01284-f001){ref-type="fig"}). All of them had "very high resistance" to fusidic acid and teicoplanin; "high resistance" to clindamycin; but, "very low resistance" to enrofloxacin ([Figure 4](#ijerph-15-01284-f004){ref-type="fig"}f). However, they had resistance levels that were "very high resistance" and "high resistance" (combined) to some popular antimicrobials in Nigeria: Amoxicillin (30%), amoxicillin-clavunanic aicd (65%), ampicillin (82%), ampicillin-cloxacillin (20%), aztreonam (15%), cefotaxime (15%), ceftazidime (15%), cefuroxime (35%), chloramphenicol (50%), ciprofloxacin (15%), cloxacillin (30%), erythromycin (55%), nalidixic acid (40%), nitrofuran (30%), ofloxacin (30%), Oxacillin (100(50/50)%), penicillin (75%), perfloxacin (20%), sparfloxacin (25%), streptomycin (50%), sulfamethoxazole (60%), co-trimoxazole (50%), tetracycline (75%), tobramycin (35%), trimethoprim (100(50/50)%), vacomycin (100(50/50)%), carbenicillin (20%), mezlocillin (30%), ticarcillin clavulanate (30%), cefoperazone (30%), lomeofloxacin (30%), and fosfomycin (35%) ([Figure 4](#ijerph-15-01284-f004){ref-type="fig"}f, [Figure S18](#app1-ijerph-15-01284){ref-type="app"}).

3.2. Antimicrobial Residue Studies (ARS) {#sec3dot2-ijerph-15-01284}
----------------------------------------

Summarized in [Table 5](#ijerph-15-01284-t005){ref-type="table"}, in this category, 16 studies were identified that dealt with antimicrobial residues in animals and the environment between 2000 and 2016. We considered published research involving qualitative and quantitative assessment of antimicrobial residues in tested samples. We observed the geographical spread of the studies in this category was poor and was skewed to the South West of Nigeria, with few studies in the South East, North Central, and North West, and no studies from the North East and South South ([Table 5](#ijerph-15-01284-t005){ref-type="table"}, [Figure S3](#app1-ijerph-15-01284){ref-type="app"}). The test procedures utilized by the researchers in the studies included microbiological assay (MA), immunological assay, and chromatography. Specifically, the Ridascreen chloramphenicol ELISA kits, Premi test kit (version 0505, Gelen contain *Bacillus stearothermophilus*), MA (seeded with *Bacillus subtilis*), MA (seeded with *Bacillus stearothermophilus*), microbial inhibition test (contain *Micrococcus luteus*), liquid chromatography, High Performance Liquid Chromatography (HPLC), four plate agar diffusion test (FPT), antibody-online ELISA kits, and the agar diffusion method was used ([Table 5](#ijerph-15-01284-t005){ref-type="table"}, [Figure 5](#ijerph-15-01284-f005){ref-type="fig"}a). The reference drugs used for the measurement of residue in all studies singly or in pairs were penicillin, amoxicillin, oxytetracycline, and chloramphenicol, and some researchers only measured antimicrobial residue without mentioning a specific drug ([Table 5](#ijerph-15-01284-t005){ref-type="table"}, [Figure 5](#ijerph-15-01284-f005){ref-type="fig"}a). Using a unified scale developed ([Table 2](#ijerph-15-01284-t002){ref-type="table"}), no study revealed "No residue"; while they all reported different levels of residue ([Table 5](#ijerph-15-01284-t005){ref-type="table"}, [Figure 5](#ijerph-15-01284-f005){ref-type="fig"}a,b). Tetracycline demonstrated to be the most researched ([Figure 5](#ijerph-15-01284-f005){ref-type="fig"}a), with reports demonstrating about 40% as a "Very high residue" level ([Figure 5](#ijerph-15-01284-f005){ref-type="fig"}b). Other antibiotics demonstrated lower "Very high residue" levels, with the exception of amoxicillin as shown in [Figure 5](#ijerph-15-01284-f005){ref-type="fig"}a,b ([Table 5](#ijerph-15-01284-t005){ref-type="table"}, [Figure 5](#ijerph-15-01284-f005){ref-type="fig"}b).

3.3. Antiseptics and Disinfectant Chemicals {#sec3dot3-ijerph-15-01284}
-------------------------------------------

Only one study identified human and chicken isolates of *Campylobacter jejuni* to show resistance to at least 19 different commonly used chemicals to control microbes \[[@B72-ijerph-15-01284]\].

4. Discussion {#sec4-ijerph-15-01284}
=============

We found that several patterns of multidrug resistance were reported in the different studies reviewed and confirmed high levels of resistance to various antimicrobials and common chemical agents \[[@B76-ijerph-15-01284],[@B77-ijerph-15-01284],[@B78-ijerph-15-01284],[@B79-ijerph-15-01284]\]. mostly used in Nigeria for prophylactic and therapeutic purposes in animals, as well as for the control and management of multiple bacterial pathogens encountered in veterinary and human medical environments \[[@B76-ijerph-15-01284]\]. These corroborated the reports of some researchers that antibiotics were readily available over the counter (without prescription) against the existing legislation, prompting a very high level of self-medication \[[@B77-ijerph-15-01284]\].

The geographical spread of the reviewed studies showed that the problem of AMR is developing nationwide despite increased awareness demonstrated by the number of studies over time. Few human samples were involved in this study where the researchers collected samples from humans along with other samples without separating the result based on sample population. The results in this study, therefore, reflected an interaction with humans. The overall outcome is an indication towards the situation in humans. However, a similar evaluation in the human health system like the current study had revealed that *Escherichia coli*, *Shigella*, *Salmonella Typhimurium*, and *S. Enteritidis* were more isolated in human diagnostic samples, with evidence of zoonotic infections \[[@B78-ijerph-15-01284]\]. Patterns of antimicrobial resistance in humans are similar to what we have also established in animal populations and the environment as indicated in this work. Resistance to penicillin, tetracycline, ampicillin, nalixidic acid, chloramphenicol, and cotrimaxole, among others, has been established in humans \[[@B78-ijerph-15-01284]\]. Whether the patterns in humans, animals, and the environment have some association cannot be established in this study, but anecdotal evidence suggests that food animals are often slaughtered and pass into the human food chain without the establishment of residual antimicrobials. We found from observation of study populations that camels were relatively free compared to other animals, but this is only in one study. We are careful to make deductions in this regards as a single study may be tricky to make predictions on the level of antimicrobials in camels, although field situation does not support the widespread use of antibiotics in camels. Also, other studies also demonstrated very low levels of AMR in camels. These studies suggested that the situation of AMR reported may be from the predictor of production management because the herders rarely use antimicrobials in camels in comparison to their use in other food animals \[[@B38-ijerph-15-01284],[@B44-ijerph-15-01284]\].

*Staphylococcus* was the only organism included in all studies in all geopolitical zones and had the widest spatial spread. Therefore, the analysis of studies on *Staphylococcus* had the greatest national reflection of the situation of AMR in Nigerian food animals and the environment. All studies on *Staphylococcus* reported very high levels of resistance to ampicillin. This corroborated the report that ampicillin and its combinations were the most consumed over-the-counter (self-medicated) drugs by humans and in animals in Nigeria \[[@B77-ijerph-15-01284]\]. This is of great concern because ampicillin is a third generation and ampicillin-cloxacillin is a fourth generation, both of β-lactams. Although, *E. coli* was the most studied, *Pseudomonas* spp. had the highest AMR because this pathogen demonstrated resistance to all antibiotics tested. Also, *Salmonella* demonstrated greater AMR than *E. coli.*

Observations of AMR within the classes of antibiotics along the generation reflected higher percentages of resistance in the antibiotics belonging to the β-lactam derivatives and quinolones of the third and fourth generation, and aminoglycosides. This raised further concerns of the threat posed by AMR. These concerns are heightened as these drugs are listed by WHO as critically important antibiotics required in the management of severe disease conditions. Considering the concerns raised by the drop in global inventions and lack of advances in the production of new antibiotics in the last three decades, which has necessitated monitoring of the circulation of antibiotics worldwide, this current situation is critical. WHO, in response to the above, produced and categorized all antibiotics, which is regularly updated yearly. Therefore, the heightened concerns are necessary to stimulate the Nigerian government and the "One Health Platform", which is under formation, to be proactive towards monitoring, improving, and controlling the current trend.

The reported rate of "high to very high level" of residue levels in the ARS is a confirmation of the demonstration of resistance levels in the AMR studies. All reference drugs tested in the ARS are commonly used in human and food animals in Nigeria \[[@B79-ijerph-15-01284]\]. Very high levels of drug residue in goats' milk (100%) is of concern. This portends a problem of AMR of food origins in humans \[[@B62-ijerph-15-01284]\]. Meanwhile, the high drug residues in Nigeria food delicacies, including muscle, liver, kidney, and milk, means that human exposure risk is high.

High level of resistance implies that most antibiotics are insensitive to most pathogens in the Nigerian environment. This has also affected antimicrobials' use as antiseptics. These high levels of residues and AMR found in food animals consumed by humans and discharged into environments sustain the AMR pool in addition to the observed resistance by chemicals commonly used as antiseptics to control infection at the point of entrance. This portends a high potential risk to public health management and necessitates the establishment of an institutionalized system that will establish, monitor, control, and promote good antimicrobial stewardship using a one health approach to reduce the current spread of antimicrobial resistance.

Finally, high levels of multiple antibiotic resistance have been observed against many microbial organisms affecting humans and animals. However, most of the studies conducted to date do not use international standards in the delivery of the research results. Future research, in this regard, must carefully consider global standards as part of their methods to engage in carrying out research in Nigeria.

5. Limitations {#sec5-ijerph-15-01284}
==============

It was difficult to harmonize our results based on the various AMRS approaches used in studies available for assessment. Moreover, in many of the studies, the Kirby-Baeur method was used, but adequate reference to standards from either Clinical & Laboratory Standards Institute (CLSI) or the European Committee on Antimicrobial Susceptibility Testing (EUCAST) was not provided.

Studies on antibiotics residues were scarce in Nigeria during the years under consideration, with limited studies available for analysis. The methods in most of the studies considered commercial kits, with a dearth of in-depth information on the procedures, which should have given ample opportunity to compares the biases in the methods used in the various residue studies. Relevant equipment that should support such studies on residue testing was wanting at the time of these studies in Nigeria.

6. Conclusions {#sec6-ijerph-15-01284}
==============

Multidrug resistance has shown a heightened rise in Nigeria based on this study. The need to use international standards to evaluate most studies on AMR nationwide, in view of the variance of these standards, is necessary. Most of the antimicrobials observed in this study are on the WHO 2017 list of essential antimicrobials and are also listed in OIE 2017 Terrestrial animal health code has, thus, necessitated the evaluation of the situation of AMR in humans \[[@B76-ijerph-15-01284],[@B80-ijerph-15-01284]\].

It is necessary to design a carefully planned, multi-sectoral, surveillance plan, which can be adopted for research and diagnostic purposes in various aspect of AMR. The need for standardization in all studies in the future and, possibly, the development of guidelines that should harmonize studies across platforms using the "One Health Approach" is imperative. This should target the promotion of good practices and antimicrobial stewardship, which should be enforced by the government, with the cooperation of all stakeholders

The relevant ministries and government departments should enforce: Registration and monitoring of animal production premises, especially, food producing animals; improvement of biosecurity compliance of food animal environments; prohibition of the use of antibiotics for growth promotion and prophylactic treatment; and putting in place a system to implement drug withdrawal periods in food animals.

More detailed descriptions of the results (figures) are available in the [Supplementary materials](#app1-ijerph-15-01284){ref-type="app"}, which are available online.

The following are available online at <http://www.mdpi.com/1660-4601/15/6/1284/s1>, Figure S1: Flow chart of the methodological strategy (PRISMA 2009 Flow Diagram), Figure S2: Nigeria geopolitical zonal spread of the AMRS reports, Figure S3: Geopolitical zonal spread of the Antimicrobial Residue reports, Figure S4a: Level of resistance within generation of antimicrobials tested, Figure S4b: Proportional (%) pattern of resistance levels within generation of antimicrobials tested, Figure S5a: Frequency of Antimicrobial Resistance levels of classes of antibiotics, Figure S5b: Antimicrobial resistance patterns within classes along generation of antibiotics, Figure S6: Antimicrobial resistance patterns of β-lactam derivatives antibiotics, Figure S7: Antimicrobial resistance patterns of Quinolones, Figure S8: Antimicrobial resistance patterns of Aminoglycosides, Figure S9: Antimicrobial resistance patterns of Macrolide, Phenicol, and Tetracycline, Figure S10: Antimicrobial resistance patterns of Sulfonamides derivatives, Figure S11: Frequency of antimicrobial resistance levels of other classes of antibiotics, Figure S12: Antimicrobial resistance patterns of other classes of antibiotics, Figure S13: Pattern of antimicrobial resistance of *Escherichia coli,* Figure S14: Pattern of antimicrobial resistance of *Salmonella,* Figure S15: Pattern of antimicrobial resistance of *Staphylococcus,* Figure S16: Pattern of antimicrobial resistance of *Pseudomonas,* Figure S17: Pattern of antimicrobial resistance of *Klebsiella,* Figure S18: Pattern of antimicrobial resistance of other bacteria, Table excel S1: Raw data AMRS, S2: Comprehensive AMRS data, S3: Categorized AMRS data analytical.

###### 

Click here for additional data file.
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###### 

Number of reports of antimicrobial resistance levels of (**a**) β-lactam derivatives; (**b**) Quinolones, (**c**) Aminiglycosides; (**d**) Macrolides, Phenicols, and Tetracyclines; and (**e**) Sulfonamides derivatives antimicrobials.
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###### 

Number of reports of antimicrobial resistance categories for (**a**) *Escherichia coli*; (**b**) *Salmonella*; (**c**) *Staphylococcus*; (**d**) *Pseudomonas*; (**e**) *Klebsiella*; and (**f**) other bacteria.
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![(**a**) Test procedure for each antibiotic tested in antimicrobial residue studies; (**b**) Relative level of antimicrobial residue. Tetracycline: Very high residue (*n* = 3), High (*n* = 1), Low (*n* = 4); Chloramphenicol: Very high (*n* = 1), High (*n* = 1), Low (*n* = 1); Amoxicillin No: (*n* = 1); Penicillin: Very high (*n* = 1), Slight high (*n* = 1), Low (*n* = 1); and Antimicrobial residue generally: Very high (*n* = 1), Slightly high (*n* = 2), Low (*n* = 1).](ijerph-15-01284-g005){#ijerph-15-01284-f005}

ijerph-15-01284-t001_Table 1

###### 

Rate of publication per year (**a**) and population groups identified in the studies (**b**).

  ---------------------------------------------------- ---------- --------- --------- -------------------
  **a. Rate of Publication per Year**                                                 
  **Publication Year**                                 **AMRS**   **ARS**   **SDA**   **Total Reports**
  2001                                                            1                   1
  2002                                                            2                   2
  2003                                                                      1         1
  2005                                                            1                   1
  2007                                                 2                              2
  2008                                                 1                              1
  2009                                                 4                              4
  2010                                                 4          1                   5
  2011                                                 2          1                   3
  2012                                                 6          7                   13
  2013                                                 7          1                   8
  2014                                                 4          1                   5
  2015                                                 5                              5
  2016                                                 7          1                   8
  Total                                                42         16        1         59
  **b. Population Groups Identified in the Studies**                                  
  **Sample Population**                                **AMRS**   **ARS**   **SDA**   **Total Reports**
  Environment                                          45         \-        1         46
  Cattle                                               28         6         \-        34
  Poultry                                              26         6         \-        32
  Pig                                                  10         2         \-        12
  Goat                                                 6          3         \-        9
  Vegetables                                           3          \-        \-        3
  Human                                                3          \-        \-        3
  Bats                                                 2          \-        \-        2
  Camel                                                2          \-        \-        2
  Sheep                                                2          \-        \-        2
  Fish                                                 1          1         \-        1
  Total                                                128        18        1         146
  ---------------------------------------------------- ---------- --------- --------- -------------------

AMRS: Antimicrobial resistance studies. ARS: Antimicrobial residue studies. SDA: Surface disinfectants and antiseptics. [Table 1](#ijerph-15-01284-t001){ref-type="table"}: This is a table to show the number of studies for different measurement parameters: (**a**) Showed the number of studies on each measured parameter for each year; and (**b**) showed the total number of reports of appearance of each population group for each measurement parameter.

ijerph-15-01284-t002_Table 2

###### 

Categorization for the measure of resistance or residue level.

  Group Scale   Categorization   Antimicrobial Resistance Studies                  Antimicrobial Residue Studies
  ------------- ---------------- ------------------------------------------------- -------------------------------
  **1**         ≤1%              Sensitive or No resistance                        No residue
  **2**         \>1 ≤ 24%        Moderately sensitive or very low resistance       Low residue
  **3**         \>24 ≤ 50%       Weakly sensitive or Low resistance                Slightly high residue
  **4**         \>50 ≤ 74%       Low sensitive or High resistance                  High residue
  **5**         \>74%            Very low (no) sensitive or Very high resistance   Very high residue

[Table 2](#ijerph-15-01284-t002){ref-type="table"}: This is a table showing the scale developed to measure the level of resistance or residue in a harmonized form from different diverse measurements from the several studies. Percentage referred to the proportion of resistant microbe populations (species) per study.

ijerph-15-01284-t003_Table 3

###### 

List of antibiotics used and the number of reports of each antimicrobial resistance.

  Antibiotics in Peer-Reviewed Studies (n)   Class               Generation   Number of Reports & Category of Resistance Level                           
  ------------------------------------------ ------------------- ------------ -------------------------------------------------- ----- ----- ----- ----- ------
  Amikacin (AMK) (5)                         Aminoglycoside      NGC          1                                                  0     3     6     7     17
  Amoxicillin (AMX) (10)                     β-lactam            3            17                                                 4     10    8     1     40
  Amoxycillin-clavunanic acid (AMC) (23)     β-lactam +          4            18                                                 7     9     4     7     45
  Ampicillin (AMP) (20)                      β-lactam            3            22                                                 5     5     7     8     47
  Ampicillin-cloxacillin (APX) (3)           β-lactam            4            4                                                  2     5     4     3     18
  Ampicillin-sulbactam (AMS) (1)             β-lactam +          4            0                                                  0     0     3     0     3
  Apramycin (APR) (5)                        Aminoglycoside      NGC          0                                                  0     0     0     5     5
  Aztreonam(AZT) (5)                         β-lactam            1            2                                                  0     2     7     4     15
  Cabenicillin (CBN) (3)                     β-lactam            4            2                                                  1     1     3     1     8
  Cefalexin (CLX) (1)                        β-lactam            2            0                                                  0     0     0     1     1
  Cefalotin (CLT) (3)                        β-lactam            1            0                                                  0     0     4     1     5
  Cefazoline (CFZ) (1)                       β-lactam            1            0                                                  0     0     2     1     3
  Cefepime (CFP) (3)                         β-lactam            4            1                                                  0     0     0     6     7
  Cefixime (CFX) (1)                         β-lactam            3            0                                                  0     1     0     0     1
  Cefoperazone (CPZ) (1)                     β-lactam            3            1                                                  1     3     0     1     6
  Cefotaxime (CTX) (10)                      β-lactam            3            2                                                  1     3     2     10    18
  Cefoxitin (CXT) (4)                        β-lactam            2            1                                                  0     1     0     4     6
  Cefpodoxime (CPM) (2)                      β-lactam            3            0                                                  1     0     2     1     4
  Ceftazidime (CAZ) (6)                      β-lactam            3            5                                                  1     2     3     7     18
  Ceftiofur (XNL) (6)                        β-lactam            3            0                                                  0     0     0     6     6
  Ceftriaxone (CRO) (8)                      β-lactam            3            2                                                  2     13    13    3     33
  Cefuroxime (CXM) (6)                       β-lactam            2            4                                                  0     3     3     7     17
  Chloramphenicol (CHL) (21)                 Phenicol            NGC          16                                                 3     11    12    6     48
  Ciprofloxacin (CIP) (30)                   Quinolone           2            8                                                  6     8     28    23    73
  Clindamycin (CLI) (5)                      Macrolide           NGC          0                                                  3     1     1     0     5
  Cloxacillin (CXL) (4)                      β-lactam            2            2                                                  0     2     0     0     4
  Colistin (COL/CT) (7)                      Polypeptide         1            0                                                  0     0     0     7     7
  Enrofloxacin (ENR) (3)                     Quinolone           2            1                                                  0     1     1     0     3
  Ertapenem (ETP) (1)                        β-lactam            NGC          0                                                  0     0     0     3     3
  Erythromycin (E) (17)                      Macrolide           NGC          18                                                 2     12    3     4     39
  Florfenicol (FFC) (6)                      Phenicol            NGC          0                                                  0     0     2     4     6
  Fosfomycin (FFM) (1)                       Organophosphate     NGC          2                                                  1     2     1     0     6
  Fusidic acid (FUA) (3)                     Steroid             NGC          2                                                  0     0     1     0     3
  Gentamycin (CN/GEN) (33)                   Aminoglycoside      NGC          7                                                  2     17    29    26    81
  Imipenem (IMP) (4)                         β-lactam            NGC          1                                                  0     0     2     6     9
  Kanamycin (K) (2)                          Aminoglycoside      NGC          0                                                  0     1     1     0     2
  Levofloxacin (LVF) (1)                     Quinolone           3            0                                                  1     3     1     1     6
  Linezolid (LIZ) (2)                        Oxazolidinone       NGC          0                                                  0     0     1     1     2
  Lomeofloxacin (LMF) (1)                    Quinolone           2            2                                                  2     2     0     0     6
  Nalidixic acid (NAL) (16)                  Quinolone           1            7                                                  5     9     9     6     36
  Neomycin (N) (8)                           Aminoglycoside      NGC          1                                                  1     4     6     5     17
  Nitrofuran (NIT) (8)                       Furan               NGC          5                                                  6     4     5     2     22
  Norfloxacin (NOR) (3)                      Quinolone           2            0                                                  0     2     3     1     6
  Meropenem (MPM) (2)                        β-lactam            NGC          1                                                  0     0     0     3     4
  Mezlocillin (MZC) (1)                      β-lactam            4            2                                                  1     2     0     1     6
  Mupirocin (MP) (2)                         Carbolic acid       NGC          0                                                  0     0     0     2     2
  Ofloxacin (OFX) (11)                       Quinolone           2            5                                                  1     9     17    8     40
  Oxacillin (OX) (7)                         β-lactam            2            3                                                  1     1     1     3     9
  Penicillin (P) (6)                         β-lactam            1            7                                                  0     1     1     1     10
  Pefloxacin (PEF) (9)                       Quinolone           2            10                                                 1     5     13    15    44
  Piperacillin (PPC) (1)                     β-lactam            4            0                                                  1     0     0     0     1
  Piperacillin-tazobactam (PTB) (4)          β-lactam + β-LI     4            1                                                  0     2     1     9     13
  Quinupristin (QUI) (1)                     Streptogramins      2            0                                                  0     1     0     0     1
  Sparfloxacin (SPF) (4)                     Quinolone           3            6                                                  0     7     12    1     26
  Rifampicin (RIF) (1)                       Ansamycin           NGC          0                                                  0     0     1     0     1
  Spectinomycin (SPE) (6)                    Aminoglycoside      NGC          0                                                  0     1     2     4     7
  Streptomycin (S) (22)                      Aminoglycoside      NGC          17                                                 10    16    13    9     65
  Sulphadimidine (SDN) (1)                   Sulfonamides        NGC          8                                                  0     0     0     1     9
  Sulfamethoxazole (SMX) (10)                Sulfonamides        NGC          7                                                  2     2     4     1     16
  Triple sulphur (TS) (1)                    Sulfonamides        NGC          1                                                  0     0     0     0     1
  Co-trimoxazole (COT) (17)                  Sulfonamides + DI   NGC          22                                                 9     14    9     3     57
  Teicoplan (TCP) (1)                        Glycopeptide        NGC          6                                                  0     0     0     0     6
  Tetracycline (T) (30)                      Tetracycline        NGC          32                                                 10    15    8     7     72
  Ticarcillin (TCC) (2)                      β-lactam            4            1                                                  1     2     2     3     9
  Tigecycline (TGC) (1)                      Tetracycline        NGC          0                                                  0     0     0     3     3
  Tobramycin (TMN) (3)                       Aminoglycoside      NGC          1                                                  0     2     3     4     10
  Trimethoprim (TMP) (10)                    DI                  NGC          4                                                  4     3     1     2     14
  Vancomycin (V) (4)                         Glycopeptide        NGC          1                                                  2     0     1     2     6
  Total (42)                                                                  289                                                100   223   266   261   1139

NGC: No generation classification. 1,2,3 and 4: First and second generation antibiotics, respectively. β-lactam + β-LI : β-lactam + β-lactamase inhibitor. β-lactam + means β-lactam combined with another antibiotics; DI: Diaminopyrimidine inhibitor. Sulfonamides + DI: Sulfonamides + Diaminopyrimidine inhibitor. (n): Number of peer reviewed studies for each antibiotic are placed in bracket after each antibiotic.
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###### 

Number of reports of each resistance level category within the classes of antimicrobial in the Antimicrobial resistance studies.

  Class of Antimicrobials   Number of Reports of Each Resistance Level Category                           
  ------------------------- ----------------------------------------------------- ----- ----- ----- ----- -------------
  Aminoglycoside            27                                                    13    44    60    60    204 (17.9%)
  Ansamycin                 0                                                     0     0     1     0     1 (0.09%)
  Carbolic acid             0                                                     0     0     0     2     2 (0.18)
  DPI                       4                                                     4     3     1     2     14 (1.2)
  Furan                     5                                                     6     4     5     2     22 (1.9)
  Glycopeptide              7                                                     2     0     1     2     12 (1.1%)
  Macrolide                 18                                                    5     13    4     4     44 (3.9)
  Organophosphate           2                                                     1     2     1     0     6 (0.5%)
  Oxazolidinone             0                                                     0     0     1     1     2 (0.16)
  Phenicol                  16                                                    3     11    14    10    54 (4.8%)
  Polypeptide               0                                                     0     0     0     7     7 (0.6%)
  Quinolone                 39                                                    16    46    84    55    240 (21.1%)
  Steroid                   2                                                     0     0     1     0     3 (0.2%)
  Streptogramins            0                                                     0     1     0     0     1 (0.08)
  Sulfonamides              16                                                    2     2     4     2     26 (2.3%)
  Sulfonamides + DI         22                                                    9     14    9     3     57 (5.0%)
  Tetracycline              32                                                    10    15    8     10    75 (6.6%)
  β-lactam                  80                                                    22    57    64    85    308 (27.0%)
  β-lactam + β-LI           19                                                    7     11    8     16    61 (5.4%)
  Total                     289                                                   100   223   266   261   1139 (100%)

DI = Diaminopyrimidine inhibitor β-LI = β-lactamase inhibitor.
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###### 

Summary evaluation of antimicrobial residue studies.

  Ref.     Sample         Zone                             Test Procedure   Positive Tested Antimicrobial Residue Level                                                                                                                                  
  -------- -------------- -------------------------------- ---------------- --------------------------------------------- ---- ----------------------------------------------------- ----------------- ----------- ------------------ ------------------ -------------------------
  **56**   Cattle         Liver, kidney & muscle           180              Ogun Lagos                                    SW   Agar diffusion method                                 Low (16.63%)      \-          \-                 \-                 \-
  **57**   Cattle         Urine                            500              Zaria                                         NW   Microbial Inhibition Test with *Micrococcus luteus*                     \-          \-                 \-                 Low (7.4%)
  **58**   Goat and pig   liver, kidney & muscle           360              Ogun Lagos                                    SW   Agar diffusion method                                 Low (15.6%)       \-          \-                 \-                 \-
  **59**   Poultry        Imported layer birds meat        100              Ogun, Lagos, Oyo                              SW   Microbiological assay seeded with B.S 1               Low (14%)         \-          \-                 \-                 \-
  **60**   Cattle         Beef                             180              Akure                                         SW   High Performance Liquid Chromatography                High (54.4%)      \-          \-                 \-                 \-
  **61**   Poultry        Eggs                             35               Enugu                                         SE   Microbiological assay seeded with B.S 2               \-                \-          \-                 \-                 Slightly high (30--36%)
  **62**   Goat           Milk                             166              Ibadan,                                       SW   Liquid Chromatography                                 \-                \-          Very high (100%)   Very high (100%)   \-
  **63**   Poultry        Chicken egg                      125              Ibadan                                        SW   High Performance Liquid Chromatography                Very high \>80%   \-          \-                 \-                 \-
  **64**   Goat and pig   Muscle, liver & kidney           240              Nsukka                                        SE   Four plate agar diffusion test (FPT)                  \-                \-          \-                 \-                 Slightly high 25--30%
  **65**   Cattle         Kidney, Liver, Muscle, Urine     448              Abuja                                         NC   Premi test kit, version 0505, Gelen contain B.S 2     \-                \-          \-                 \-                 Very high 89.3%
  **66**   Poultry        Eggs, muscles, liver, & kidney   168              Ibadan                                        SW   Ridascreen CHL ELISA kits                             \-                High        \-                 \-                 \-
  **67**   Fish           Fresh & frozen fish              60               Ibadan                                        SW   High Performance Liquid Chromatography                Very high         Very high   \-                 \-                 \-
  **68**   Poultry        Frozen chicken                   100              Lagos & Ibadan                                SW   High Performance Liquid Chromatography                Very high         \-          \-                 \-                 \-
  **69**   Cattle         Organs: kidney, liver, muscles   90               South west                                    SW   High Performance Liquid Chromatography                Low               \-          \-                 Low                \-
  **70**   Poultry        Chicken eggs                     288              Abuja                                         NC   Antibody-online ELISA kits                            \-                Low         \-                 \-                 \-
  **71**   Cattle         Dairy products                   598              Oyo state                                     SW   High Performance Liquid Chromatography                \-                \-          \-                 Slightly high      \-

TET: Tetracycline, CHL: Chloramphenicol, AMX: Amoxicillin, PEN: Penicillin B.S 1: *Bacillus subtilis.* B.S 2: *Bacillus stearothermophilus* AR: Antimicrobial residue.
